PE20000265A1 - Composiciones que contienen virus y metodos para concentrar preparados de virus - Google Patents
Composiciones que contienen virus y metodos para concentrar preparados de virusInfo
- Publication number
- PE20000265A1 PE20000265A1 PE1999000137A PE00013799A PE20000265A1 PE 20000265 A1 PE20000265 A1 PE 20000265A1 PE 1999000137 A PE1999000137 A PE 1999000137A PE 00013799 A PE00013799 A PE 00013799A PE 20000265 A1 PE20000265 A1 PE 20000265A1
- Authority
- PE
- Peru
- Prior art keywords
- virus
- refers
- concentration
- preparation
- polyhydroxyhydrocarbon
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 10
- 238000002360 preparation method Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 241000701161 unidentified adenovirus Species 0.000 abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 238000009295 crossflow filtration Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000001471 micro-filtration Methods 0.000 abstract 1
- 238000003825 pressing Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
- 238000000108 ultra-filtration Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2446298A | 1998-02-17 | 1998-02-17 | |
| US7964398A | 1998-05-15 | 1998-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000265A1 true PE20000265A1 (es) | 2000-04-25 |
Family
ID=26698472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000137A PE20000265A1 (es) | 1998-02-17 | 1999-02-16 | Composiciones que contienen virus y metodos para concentrar preparados de virus |
Country Status (24)
| Country | Link |
|---|---|
| EP (4) | EP1054955B1 (https=) |
| JP (3) | JP4358434B2 (https=) |
| KR (5) | KR100912362B1 (https=) |
| CN (2) | CN100374551C (https=) |
| AR (3) | AR020054A1 (https=) |
| AT (3) | ATE371020T1 (https=) |
| AU (1) | AU757976B2 (https=) |
| BR (1) | BR9908015A (https=) |
| CA (2) | CA2723040A1 (https=) |
| CO (1) | CO4820440A1 (https=) |
| DE (3) | DE69942708D1 (https=) |
| DK (1) | DK1054955T3 (https=) |
| ES (2) | ES2290613T3 (https=) |
| HU (1) | HU226015B1 (https=) |
| ID (1) | ID28298A (https=) |
| IL (2) | IL137510A0 (https=) |
| MY (1) | MY141641A (https=) |
| NO (1) | NO20004104L (https=) |
| PE (1) | PE20000265A1 (https=) |
| PL (1) | PL197747B1 (https=) |
| PT (1) | PT1054955E (https=) |
| SK (1) | SK11842000A3 (https=) |
| TW (1) | TWI232107B (https=) |
| WO (1) | WO1999041416A2 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2278399T3 (es) | 1996-11-20 | 2007-08-01 | Introgen Therapeutics, Inc. | Metodo mejorado para la produccion y purificacion de vectores adenovirales. |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| DE69940354D1 (de) * | 1998-11-16 | 2009-03-12 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| EP2420247A1 (en) | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
| JP2002241311A (ja) * | 2000-12-12 | 2002-08-28 | Japan Tobacco Inc | 界面活性剤を含む医薬組成物 |
| EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
| US20030153065A1 (en) * | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
| AR038153A1 (es) * | 2002-01-18 | 2004-12-29 | Schering Ag | Formulaciones estabilizadas de adenovirus |
| NZ548495A (en) | 2004-02-23 | 2009-05-31 | Crucell Holland Bv | Virus purification methods |
| EP1815029A4 (en) | 2004-11-03 | 2009-06-10 | Introgen Therapeutics Inc | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS |
| CA2590943C (en) | 2004-12-13 | 2013-10-22 | Canji, Inc. | Cell lines for production of replication-defective adenovirus |
| DK1869171T4 (en) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| CN1961961B (zh) * | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| DE602006019916D1 (de) | 2005-12-12 | 2011-03-10 | Canji Inc | Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase |
| PL2007883T3 (pl) * | 2006-04-20 | 2012-07-31 | Wyeth Llc | Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej |
| CN102203242B (zh) | 2008-11-03 | 2013-06-12 | 克鲁塞尔荷兰公司 | 产生腺病毒载体的方法 |
| JP5879256B2 (ja) | 2009-05-02 | 2016-03-08 | ジェンザイム・コーポレーション | 神経変性障害のための遺伝子治療 |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| EP2618838A1 (en) | 2010-09-20 | 2013-07-31 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
| MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
| MX349294B (es) | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| JP6029651B2 (ja) * | 2011-04-29 | 2016-11-24 | オンコリティクス バイオテク，インコーポレーテッド | ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法 |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| JP5770952B2 (ja) | 2012-03-12 | 2015-08-26 | クルセル ホランド ベー ヴェー | 改変末端を有する組換えアデノウイルスのバッチ |
| EA026504B1 (ru) | 2012-03-22 | 2017-04-28 | Круселл Холланд Б.В. | Вакцина против rsv |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| JP6469081B2 (ja) | 2013-04-25 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された可溶性融合前ｒｓｖｆポリペプチド |
| MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
| SG11201609908VA (en) * | 2014-05-28 | 2016-12-29 | Agency Science Tech & Res | Virus reduction method |
| WO2016166088A1 (en) | 2015-04-14 | 2016-10-20 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| CN107847581B (zh) | 2015-07-07 | 2022-03-22 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| ES2839880T3 (es) | 2015-07-07 | 2021-07-06 | Janssen Vaccines & Prevention Bv | Vacuna contra el VRS |
| PH12022552125A1 (en) | 2016-04-05 | 2023-04-12 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
| KR102500970B1 (ko) | 2016-04-05 | 2023-02-17 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
| IL264119B2 (en) | 2016-05-30 | 2023-04-01 | Janssen Vaccines Prevention B V | f proteins of rsv are stabilized before fusion |
| KR102307065B1 (ko) | 2016-06-20 | 2021-09-30 | 얀센 백신스 앤드 프리벤션 비.브이. | 강력하고 균형 잡힌 양방향성 프로모터 |
| US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
| US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| WO2019021305A1 (en) * | 2017-07-24 | 2019-01-31 | Ella Foundation | VACCINE AGAINST FOOT AND MOUTH DISEASE |
| WO2019053109A1 (en) | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
| JP2022513025A (ja) | 2018-11-13 | 2022-02-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前ｒｓｖ ｆタンパク質 |
| EP3990031A4 (en) * | 2019-06-28 | 2023-08-09 | Takeda Pharmaceutical Company Limited | Adeno-associated virus purification methods |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| AU2021237818A1 (en) * | 2020-03-19 | 2022-09-29 | Ferring Ventures Ltd. | Temperature-responsive virus storage system |
| WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023020556A1 (zh) * | 2021-08-17 | 2023-02-23 | 上海行深生物科技有限公司 | 病毒制剂、用于配制病毒制剂的溶液及其用途 |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE299213C (https=) * | ||||
| US4147772A (en) * | 1976-02-03 | 1979-04-03 | Merck & Co., Inc. | Vaccine stabilizer |
| GB1575155A (en) * | 1978-04-11 | 1980-09-17 | Merck & Co Inc | Vaccine stabilizer |
| BE866330A (fr) * | 1978-04-25 | 1978-10-25 | Merck & Co Inc | Procede de fabrication d'un agent de stabilisation de vaccin |
| US5532220A (en) | 1987-08-31 | 1996-07-02 | The Regents Of The University Of California | Genetic mechanisms of tumor suppression |
| DD299213A7 (de) * | 1988-05-04 | 1992-04-09 | Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De | Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung |
| DD295927A5 (de) * | 1988-05-06 | 1991-11-14 | Saechsisches Serumwerk Gmbh Dresden, | Immobilisiertes immunologisch aktives reagens |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| KR100368686B1 (ko) * | 1994-12-29 | 2003-12-01 | 주식회사 엘지생명과학 | 수크로즈를이용한세포와바이러스의분리방법 |
| FR2742756B1 (fr) * | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
| US5789244A (en) | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
-
1999
- 1999-02-12 KR KR1020087008928A patent/KR100912362B1/ko not_active Expired - Fee Related
- 1999-02-12 CA CA2723040A patent/CA2723040A1/en not_active Abandoned
- 1999-02-12 IL IL13751099A patent/IL137510A0/xx unknown
- 1999-02-12 CN CNB998050989A patent/CN100374551C/zh not_active Expired - Fee Related
- 1999-02-12 BR BR9908015-0A patent/BR9908015A/pt not_active Application Discontinuation
- 1999-02-12 AT AT04030395T patent/ATE371020T1/de not_active IP Right Cessation
- 1999-02-12 PL PL342847A patent/PL197747B1/pl not_active IP Right Cessation
- 1999-02-12 KR KR1020007008878A patent/KR100862169B1/ko not_active Expired - Fee Related
- 1999-02-12 AU AU26538/99A patent/AU757976B2/en not_active Ceased
- 1999-02-12 KR KR1020087008929A patent/KR100918187B1/ko not_active Expired - Fee Related
- 1999-02-12 AT AT06019642T patent/ATE478945T1/de not_active IP Right Cessation
- 1999-02-12 EP EP99906690A patent/EP1054955B1/en not_active Expired - Lifetime
- 1999-02-12 ES ES04030395T patent/ES2290613T3/es not_active Expired - Lifetime
- 1999-02-12 CA CA2320419A patent/CA2320419C/en not_active Expired - Fee Related
- 1999-02-12 DE DE69942708T patent/DE69942708D1/de not_active Expired - Lifetime
- 1999-02-12 KR KR1020097022935A patent/KR101018992B1/ko not_active Expired - Fee Related
- 1999-02-12 CN CN2007101670867A patent/CN101164623B/zh not_active Expired - Fee Related
- 1999-02-12 SK SK1184-2000A patent/SK11842000A3/sk unknown
- 1999-02-12 ID IDW20001574A patent/ID28298A/id unknown
- 1999-02-12 PT PT99906690T patent/PT1054955E/pt unknown
- 1999-02-12 JP JP2000531596A patent/JP4358434B2/ja not_active Expired - Fee Related
- 1999-02-12 DK DK99906690T patent/DK1054955T3/da active
- 1999-02-12 KR KR1020097004676A patent/KR100991683B1/ko not_active Expired - Fee Related
- 1999-02-12 EP EP04030394A patent/EP1526173B1/en not_active Expired - Lifetime
- 1999-02-12 DE DE69936948T patent/DE69936948T2/de not_active Expired - Lifetime
- 1999-02-12 WO PCT/US1999/001873 patent/WO1999041416A2/en not_active Ceased
- 1999-02-12 ES ES99906690T patent/ES2272053T3/es not_active Expired - Lifetime
- 1999-02-12 HU HU0100670A patent/HU226015B1/hu not_active IP Right Cessation
- 1999-02-12 AT AT99906690T patent/ATE341614T1/de not_active IP Right Cessation
- 1999-02-12 DE DE69933433T patent/DE69933433T2/de not_active Expired - Lifetime
- 1999-02-12 TW TW088102219A patent/TWI232107B/zh not_active IP Right Cessation
- 1999-02-12 EP EP06019642A patent/EP1741777B1/en not_active Expired - Lifetime
- 1999-02-12 EP EP04030395A patent/EP1526174B1/en not_active Expired - Lifetime
- 1999-02-15 MY MYPI99000542A patent/MY141641A/en unknown
- 1999-02-16 PE PE1999000137A patent/PE20000265A1/es not_active Application Discontinuation
- 1999-02-16 CO CO99009282A patent/CO4820440A1/es unknown
- 1999-02-23 AR ARP990100656A patent/AR020054A1/es active IP Right Grant
-
2000
- 2000-07-25 IL IL137510A patent/IL137510A/en not_active IP Right Cessation
- 2000-08-16 NO NO20004104A patent/NO20004104L/no not_active Application Discontinuation
-
2006
- 2006-02-07 JP JP2006030336A patent/JP2006166925A/ja not_active Withdrawn
-
2007
- 2007-10-16 AR ARP070104577A patent/AR063315A2/es unknown
- 2007-10-16 AR ARP070104576A patent/AR063314A2/es unknown
-
2010
- 2010-07-08 JP JP2010156257A patent/JP2010213727A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000265A1 (es) | Composiciones que contienen virus y metodos para concentrar preparados de virus | |
| AR121861A2 (es) | MÉTODO PARA PREPARAR UNA COMPOSICIÓN DE IgG ENRIQUECIDA A PARTIR DE PLASMA | |
| Spelsberg et al. | Proteins of chromatin in template restriction: III. The macromolecules in specific restriction of the chromatin DNA | |
| JP2002503484A5 (https=) | ||
| JP2644946B2 (ja) | ＩｇＧ− モノクロナール抗体の精製方法及びその使用方法 | |
| JPS5944322A (ja) | 抗血友病性因子濃厚物の調製法 | |
| CA2736104A1 (en) | A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition | |
| GB1597204A (en) | Process of preparing a serum protein composition for intravenous application | |
| ES2770860T3 (es) | Métodos de purificación y/o inactivación viral | |
| WO1982002890A1 (en) | Cyclodextrin clathrate compounds of sulfur-containing compounds | |
| JPS6136228A (ja) | 肝炎表面抗原の精製方法 | |
| ES2780367T3 (es) | Nuevo método de purificación eficiente de albumina sérica humana | |
| ES2224094T3 (es) | Procedimiento para preparar seroalbumina normal (humana) esencialmente monomerica. | |
| ES2543829T3 (es) | Procedimiento para la preparación del inhibidor de proteinasa alfa-1 | |
| JPS6042207B2 (ja) | 胎盤よりプラスミノ−ゲン型活性化合物を抽出する方法 | |
| ES2203618T3 (es) | Procedimiento de purificacion de una solucion acuosa de albumina bruta. | |
| Zeppezauera et al. | A 81Br nuclear magnetic resonance study of bromide ion binding to proteins in aqueous solution | |
| JPH04506349A (ja) | タンパク質の浄化方法 | |
| SE7906137L (sv) | Rening av faktor viii | |
| ATE44750T1 (de) | Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats. | |
| Carroll et al. | Alanine uptake by isolated zooxanthellae of the mangrove jellyfish, Cassiopea xamachana. II. Inhibition by host homogenate fraction | |
| Williamson | Purification of DNA by isopycnic banding in cesium chloride in a zonal rotor | |
| JP2005245269A (ja) | 血清アルブミン多量体を含む遺伝子組換え型蛋白質 | |
| Idriss et al. | Studies on cytosolic guanylate cyclase from human placenta | |
| JP2861655B2 (ja) | ヒト尿性トリプシンインヒビター含有液状製剤及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |